Department of Pathology
  Brigham and Women's Hospital
  A teaching Affliate of Harvard Medical School
Login Skip Navigation Links
  Skip Navigation Links
HomeExpand Home





Announcement

Submit new announcement
Massimo F. Loda, M.D.

Professor of Pathology, Harvard Medical School



Academic Activities:

Office
Dana 1536
44 Binney Street
Boston,MA 02115
Email1: massimo_loda@dfci.harvard.edu
Education and Training:

Medical School 1976 - 1980 : Universita' degli Studi di Milano M.D.
Residency 7/1/85 - 6/30/88 : New England Deaconess Hospital
Fellowship 7/1/88 - 6/30/89 : New England Medical Center

Clinical Specialties:
  • Genitourinary Pathology
Research Interests:
  • Gene expression
  • Marker identification
  • Signalling pathway
  • Prostate cancer
Publication:
  1. Loda M, Cukor B, Tam S, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med, 1997; 3: 231-234.
  2. Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G Jr, Ranashinge M, Cady B, Pagano M, Loda M. Role of the cdc25A phosphatase in human breast cancer. J Clin Invest 106:753, 2000
  3. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157: 1769-75, 2000
  4. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression increases with progression towards androgen independence in human prostate cancer. J Natl Cancer Inst 92: 1918-25, 2000
  5. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 2001, 15:765-782
  6. Rossi S, Graner E, Febbo P, Weinstein L, Bubley G, Balk S and Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 2003 Aug;1(10):707-15
  7. Baron A, Migita T, Tang D, Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J Cell Biochem 2004 Jan 1;91(1):47-53
  8. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M. The isopeptidase USP2a regulates the stability of Fatty Acid Synthase in prostate cancer. Cancer Cell 5, 253-261, 2004
  9. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A. 2005 102(32):11355-60.
  10. Signoretti S, Loda M. Defining Cell Lineages in the Prostate Epithelium. Cell Cycle. 2006;5(2)
  11. Rossi S, Ou W, Tang D, Bhattacharya N, Dei Tos AP, Fletcher JA, Loda M. Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol. 2006; 209(3):369-75.
  12. Priolo C, Tang D, Brahamanda M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Zimmermann J, Febbo P, Loda M. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 2006; 66(17):8625-32
<September 2018>
SuMoTuWeThFrSa
2627282930311
2345678
9101112131415
16171819202122
23242526272829
30123456


<Tuesday, September 25, 2018>
12:00 PM

Dammin signout suite
12:00 PM

Cotran Conference Center
1:00 PM
Dr. Christopher Fletcher
Cotran Conference Center
2:00 PM

GYN 14-headed scope
2:30 PM

Autopsy suite
3:00 PM

Cotran Conference Center
Copyright 2008 - 2018, BWH Pathology, All rights reserved.